Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Hanny Al-Samkari, MD; Sujit Sheth, MD; and Mark A. Schroeder, MD, provide their clinical perspectives on new data from ASH 2020 on nonmalignant hematologic disorders, with topics including:
Presenters:
Hanny Al-Samkari, MD
Instructor
Department of Medicine
Harvard Medical School
Attending Hematologist and Clinical Investigator
Division of Hematology Oncology
Massachusetts General Hospital
Boston, Massachusetts
Sujit Sheth, MD
Professor
Department of Pediatrics
Weill Cornell Medicine
New York, New York
Mark A. Schroeder, MD
Associate Professor of Medicine
Division of Oncology
Department of Medicine
Washington University School of Medicine in St Louis
St Louis, Missouri
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the expanding treatment options for hemophilia A & B
Data on JAK2 V617F molecular response from a study of ruxolitinib in patients with polycythemia vera or essential thrombocythemia, from ASH 2022 and reported by Clinical Care Options (CCO)
New data from APPLY-PNH study of iptacopan in patients with paroxysmal nocturnal hemoglobinuria, presented at ASH 2022 and reported by Clinical Care Options (CCO)
Results from phase II trial of second-in-class oral factor D inhibitor vemircopan in previously untreated patients with PNH, presented at ASH 2022 and reported by Clinical Care Options( CCO)
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.